Manojkumar Bupathi

TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors

Scott T. Tagawa, Arjun Vasant Balar, Daniel P. Petrylak et al. · Journal of Clinical Oncology · 2021 · 507 citations · Full text

TROPHY-U-01, a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors: updated safety and efficacy outcomes

Yohann Loriot, Daniel P. Petrylak, Arash Rezazadeh Kalebasty et al. · Annals of Oncology · 2024 · 71 citations · Full text

Sacituzumab Govitecan in Combination With Pembrolizumab for Patients With Metastatic Urothelial Cancer That Progressed After Platinum-Based Chemotherapy: TROPHY-U-01 Cohort 3

Petros Grivas, Damien Pouessel, Chandler H. Park et al. · Journal of Clinical Oncology · 2024 · 64 citations · Full text

Degree of <i>MDM2</i> Amplification Affects Clinical Outcomes in Dedifferentiated Liposarcoma

Kate Lynn J. Bill, Nathan D. Seligson, John L. Hays et al. · The Oncologist · 2019 · 39 citations · Full text

TROPHY-U-01 Cohort 3: Sacituzumab govitecan (SG) in combination with pembrolizumab (Pembro) in patients (pts) with metastatic urothelial cancer (mUC) who progressed after platinum (PLT)-based regimens.

Petros Grivas, Damien Pouessel, Chandler H. Park et al. · Journal of Clinical Oncology · 2022 · 35 citations

Cancer Management, Immunology, Immunotherapeutics +20